Skip to content

Menu

Network Sub-MenuBrowse by SubjectBrowse by PublisherJoin the NetworkGet StartedSubscribeSupport

Search

Close

Enter Search Terms

Philip Katz

ID: 1b834083-2619-30fb-68c4

/

Unclaimed

/

Organization: Hogan Lovells

FDA and EMA Address Quality and Manufacturing Challenges for Breakthrough Therapies Undergoing Expedited Approval

Focus on Regulation · August 5, 2019

FDA guidance may ease path to biosimilar interchangeability

Focus on Regulation · May 15, 2019

FDA publishes final guidance on ANDA/505(b)(2) NDA pathways

Focus on Regulation · May 10, 2019

FDA’s Bendeka decision reverses approvals of Treanda generics

Focus on Regulation · February 21, 2019

Would you like an extra application with that? FDA mulls requiring dual applications for combination products

Focus on Regulation · February 8, 2019

Previous

12 3 4

Next

Claim This Record

Is this your profile? Upgrade to display your full biography, collected works, social connections, practice areas, and more.

Enhance Your Profile

Call us at 1-800-913-0988 or email sales@lexblog.com.

Facebook LinkedIn Twitter RSS

About LexBlog
The Field We Built
Our Beliefs
Our Team
Contact LexBlog

Disclaimer
Editorial Policy
Terms of Service

Get Started
Publishing Solutions
Compass

Submit a Request
Support Center
System Status

Copyright © 2026, LexBlog, Inc. All Rights Reserved.

Law blog design & platform by LexBlog